219 related articles for article (PubMed ID: 23661005)
1. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
Hage C; Rausch V; Giese N; Giese T; Schönsiegel F; Labsch S; Nwaeburu C; Mattern J; Gladkich J; Herr I
Cell Death Dis; 2013 May; 4(5):e627. PubMed ID: 23661005
[TBL] [Abstract][Full Text] [Related]
2. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.
Isayev O; Rausch V; Bauer N; Liu L; Fan P; Zhang Y; Gladkich J; Nwaeburu CC; Mattern J; Mollenhauer M; Rückert F; Zach S; Haberkorn U; Gross W; Schönsiegel F; Bazhin AV; Herr I
Oncotarget; 2014 Jul; 5(13):5177-89. PubMed ID: 25015789
[TBL] [Abstract][Full Text] [Related]
5. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
[TBL] [Abstract][Full Text] [Related]
6. The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer.
Jia Y; Gu D; Wan J; Yu B; Zhang X; Chiorean EG; Wang Y; Xie J
Oncogene; 2019 Mar; 38(10):1764-1777. PubMed ID: 30382189
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication.
Forster T; Rausch V; Zhang Y; Isayev O; Heilmann K; Schoensiegel F; Liu L; Nessling M; Richter K; Labsch S; Nwaeburu CC; Mattern J; Gladkich J; Giese N; Werner J; Schemmer P; Gross W; Gebhard MM; Gerhauser C; Schaefer M; Herr I
Oncotarget; 2014 Mar; 5(6):1621-34. PubMed ID: 24742583
[TBL] [Abstract][Full Text] [Related]
8. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.
Wang K; Baldwin GS; Nikfarjam M; He H
Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G632-G640. PubMed ID: 30844294
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.
Hu G; Li F; Ouyang K; Xie F; Tang X; Wang K; Han S; Jiang Z; Zhu M; Wen D; Qin X; Zhang L
Int J Oncol; 2012 Mar; 40(3):798-806. PubMed ID: 22076649
[TBL] [Abstract][Full Text] [Related]
11. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
13. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
14. c-Met is a marker of pancreatic cancer stem cells and therapeutic target.
Li C; Wu JJ; Hynes M; Dosch J; Sarkar B; Welling TH; Pasca di Magliano M; Simeone DM
Gastroenterology; 2011 Dec; 141(6):2218-2227.e5. PubMed ID: 21864475
[TBL] [Abstract][Full Text] [Related]
15. Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib.
Liu L; Aleksandrowicz E; Fan P; Schönsiegel F; Zhang Y; Sähr H; Gladkich J; Mattern J; Depeweg D; Lehner B; Fellenberg J; Herr I
Cell Death Dis; 2014 Oct; 5(10):e1471. PubMed ID: 25321478
[TBL] [Abstract][Full Text] [Related]
16. Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition of LKB1 and activation of AMPK in PDACs.
Cheng X; Kim JY; Ghafoory S; Duvaci T; Rafiee R; Theobald J; Alborzinia H; Holenya P; Fredebohm J; Merz KH; Mehrabi A; Hafezi M; Saffari A; Eisenbrand G; Hoheisel JD; Wölfl S
Mol Oncol; 2016 Jun; 10(6):806-24. PubMed ID: 26887594
[TBL] [Abstract][Full Text] [Related]
17. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
18. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
Binenbaum Y; Na'ara S; Gil Z
Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Solca F; Modjtahedi H
Int J Oncol; 2016 Mar; 48(3):908-18. PubMed ID: 26781210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]